Ironwood Pharmaceuticals Inc (IRWD) concluded trading on Thursday at a closing price of $0.88, with 2.98 million shares of worth about $2.62 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -79.03% during that period and on April 24, 2025 the price saw a gain of about 13.45%. Currently the company’s common shares owned by public are about 160.21M shares, out of which, 156.66M shares are available for trading.
Stock saw a price change of 17.16% in past 5 days and over the past one month there was a price change of -41.42%. Year-to-date (YTD), IRWD shares are showing a performance of -80.16% which decreased to -89.10% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.59 but also hit the highest price of $8.45 during that period. The average intraday trading volume for Ironwood Pharmaceuticals Inc shares is 3.97 million. The stock is currently trading -17.02% below its 20-day simple moving average (SMA20), while that difference is down -37.33% for SMA50 and it goes to -75.98% lower than SMA200.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) currently have 160.21M outstanding shares and institutions hold larger chunk of about 101.54% of that.
The stock has a current market capitalization of $142.18M and its 3Y-monthly beta is at 0.49. PE ratio of stock for trailing 12 months is 81.36, while it has posted earnings per share of $0.01 in the same period. Its PEG reads 0.58 and has Quick Ratio of 4.69. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IRWD, volatility over the week remained 13.39% while standing at 13.02% over the month.
Stock’s fiscal year EPS is expected to rise by 769.75% while it is estimated to increase by 289.35% in next year. EPS is likely to grow at an annualized rate of 141.01% for next 5-years, compared to annual growth of -47.49% made by the stock over the past 5-years.
On April 14, 2025, Citizens JMP Downgrade their recommendations, while on September 09, 2024, Leerink Partners Initiated their ratings for the stock with a price target of $5. Stock get an Equal weight rating from CapitalOne on August 08, 2024.
